TCM
REGN icon

Twin Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Twin Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$937K Sell
1,213
-32
-3% -$24.5K 0.12% 171
2025
Q4 		$961K Buy
1,245
+19
+2% +$12.9K 0.12% 165
2025
Q3 		$689K Buy
+1,226
New +$693K 0.09% 201
2025
Q1 		– Sell
-3,655
Closed -$2.6M – 316
2024
Q4 		$2.6M Buy
3,655
+101
+3% +$84.8K 0.29% 94
2024
Q3 		$3.74M Sell
3,554
-352
-9% -$392K 0.42% 59
2024
Q2 		$4.11M Buy
3,906
+119
+3% +$115K 0.48% 47
2024
Q1 		$3.64M Sell
3,787
-214
-5% -$203K 0.45% 59
2023
Q4 		$3.51M Sell
4,001
-94
-2% -$77.4K 0.46% 59
2023
Q3 		$3.37M Sell
4,095
-313
-7% -$246K 0.48% 51
2023
Q2 		$3.17M Sell
4,408
-230
-5% -$177K 0.41% 64
2023
Q1 		$3.81M Sell
4,638
-529
-10% -$399K 0.52% 48
2022
Q4 		$3.73M Sell
5,167
-239
-4% -$176K 0.48% 57
2022
Q3 		$3.72M Sell
5,406
-77
-1% -$48.5K 0.5% 50
2022
Q2 		$3.24M Buy
5,483
+329
+6% +$214K 0.41% 70
2022
Q1 		$3.6M Buy
5,154
+29
+0.6% +$18.3K 0.39% 77
2021
Q4 		$3.24M Sell
5,125
-448
-8% -$275K 0.32% 104
2021
Q3 		$3.37M Sell
5,573
-579
-9% -$359K 0.35% 91
2021
Q2 		$3.44M Buy
6,152
+123
+2% +$62.3K 0.32% 105
2021
Q1 		$2.85M Sell
6,029
-829
-12% -$404K 0.28% 114
2020
Q4 		$3.31M Buy
6,858
+440
+7% +$238K 0.3% 104
2020
Q3 		$3.59M Sell
6,418
-21
-0.3% -$12.7K 0.33% 95
2020
Q2 		$4.02M Sell
6,439
-19
-0.3% -$10.8K 0.39% 79
2020
Q1 		$3.15M Sell
6,458
-170
-3% -$70.1K 0.34% 91
2019
Q4 		$2.49M Buy
6,628
+5,168
+354% +$1.74M 0.21% 148
2019
Q3 		$405K Sell
1,460
-50
-3% -$14.8K 0.03% 258
2019
Q2 		$473K Sell
1,510
-4,400
-74% -$1.46M 0.03% 260
2019
Q1 		$2.43M Buy
+5,910
New +$2.43M 0.12% 205
2016
Q1 		– Sell
-400
Closed -$217K – 285
2015
Q4 		$217K Buy
+400
New +$217K 0.02% 266
2015
Q3 		– Sell
-400
Closed -$204K – 274
2015
Q2 		$204K Buy
+400
New +$195K 0.02% 251

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Twin Capital Management's REGN Position: Q1 2026 in Review

Twin Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.6% in Q1 2026, selling an estimated $24.5K and leaving 1,213 shares worth $937K. The position accounts for 0.12% of the portfolio, ranked #171.

Twin Capital Management first reported a position in REGN in Q2 2015 and has held it in 29 quarters since. The position peaked at $4.11M in Q2 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Twin Capital Management held 1,213 shares of Regeneron Pharmaceuticals worth $937K as of Q1 2026.
  • Twin Capital Management sold 32 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $24.5K.
  • Regeneron Pharmaceuticals made up 0.12% of Twin Capital Management's portfolio in Q1 2026, its #171 holding.
  • Twin Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 29 quarters since.
  • Twin Capital Management's Regeneron Pharmaceuticals position peaked at $4.11M in Q2 2024.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.